Zoetis Inc. (NYSE:ZTS) Position Lessened by Raub Brock Capital Management LP

Raub Brock Capital Management LP cut its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 3.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 85,779 shares of the company's stock after selling 3,028 shares during the quarter. Zoetis accounts for 3.2% of Raub Brock Capital Management LP's investment portfolio, making the stock its 21st biggest holding. Raub Brock Capital Management LP's holdings in Zoetis were worth $14,123,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Callahan Advisors LLC increased its position in Zoetis by 90.4% during the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock worth $2,135,000 after buying an additional 6,221 shares in the last quarter. CIBC Asset Management Inc increased its position in Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after buying an additional 46,050 shares in the last quarter. Schroder Investment Management Group grew its position in shares of Zoetis by 2.6% in the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after purchasing an additional 6,169 shares during the period. Vanguard Group Inc. grew its position in shares of Zoetis by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after purchasing an additional 120,158 shares during the period. Finally, Portside Wealth Group LLC grew its position in shares of Zoetis by 24.7% in the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after purchasing an additional 6,672 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Wall Street Zen raised Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Morgan Stanley lowered their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Piper Sandler boosted their price target on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Stifel Nicolaus lowered their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Finally, Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $212.75.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president now owns 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.18% of the stock is currently owned by insiders.

Zoetis Stock Down 2.7%

Zoetis stock traded down $4.55 during midday trading on Friday, hitting $164.27. The stock had a trading volume of 2,973,481 shares, compared to its average volume of 2,551,305. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a market cap of $73.13 billion, a P/E ratio of 30.03, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The business has a fifty day moving average price of $158.67 and a 200 day moving average price of $164.01.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.38 earnings per share. Research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. Zoetis's dividend payout ratio (DPR) is 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.